Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Common Equity (2018 - 2025)

Historic Common Equity for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $796.3 million.

  • 10x Genomics' Common Equity rose 1213.74% to $796.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $796.3 million, marking a year-over-year increase of 1213.74%. This contributed to the annual value of $796.3 million for FY2025, which is 1213.74% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Common Equity is $796.3 million, which was up 1213.74% from $785.1 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Common Equity ranged from a high of $817.6 million in Q4 2021 and a low of $706.9 million during Q1 2025
  • Over the past 5 years, 10x Genomics' median Common Equity value was $779.7 million (recorded in 2022), while the average stood at $767.3 million.
  • Per our database at Business Quant, 10x Genomics' Common Equity soared by 10052.34% in 2021 and then plummeted by 1041.28% in 2024.
  • Over the past 5 years, 10x Genomics' Common Equity (Quarter) stood at $817.6 million in 2021, then fell by 1.45% to $805.7 million in 2022, then fell by 8.03% to $741.0 million in 2023, then fell by 4.17% to $710.1 million in 2024, then increased by 12.14% to $796.3 million in 2025.
  • Its Common Equity was $796.3 million in Q4 2025, compared to $785.1 million in Q3 2025 and $773.3 million in Q2 2025.